COVID-19 swept across the globe in a matter of months infecting millions of people. With few treatment options currently available, it is a stark reminder of the growing concern about antimicrobial-resistant infections. As the industry has pivoted to tackle COVID-19, so too is it marshaling its forces against this threat.

THOUSAND OAKS, Calif., — Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene‘s registered direct offering of ordinary shares, which maintains Amgen’s current pro rata ownership of BeiGene at approximately 20.3%. This additional investment reflects Amgen’s confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world’s second largest pharmaceutical market.

Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C, with an IPO surely not far behind.

Oragenics is bidding adieu to its lead program, a treatment designed to ward off inflammatory side effects from cancer treatments like chemotherapy and radiation. It’s halting a phase 2 study of the drug and yanking its Investigational New Drug application. The company will pivot its resources to developing a COVID-19 vaccine.

Forbion has expanded into late-stage biotech investing by holding the first close of a planned €250 million ($284 million) fund. The growth fund, which received money from Eil Lilly, will work with a who’s who of European biotech leaders to execute its investment strategy.

Japanese Big Pharma Takeda has paired with synthetic DNA services company Twist Bioscience to level up its biologics capacity.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera Therapeutics.

Nerve cell inflammation has long been linked to neurodegenerative disease, but as a byproduct rather than a cause. Over the years, scientists have debunked that theory, including Stanford Medicine’s Edgar Engleman, M.D., whose work laid the groundwork for a new company, Tranquis Therapeutics.

It’s no secret: Amyotrophic lateral sclerosis (ALS) is a tough nut to crack. And no one knows that better than Biogen, which in 2013 saw its last ALS effort, dexpramipexole, go up in flames in phase 3.

Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.